ClinicalTrials.gg
RecruitingNCT07025629DAPA-ICUUpdated Feb 23, 2026

Dapagliflozin for Cardio-renal Protection After ICU Discharge

A Phase 3 interventional study of Dapagliflozin 10 MG Oral Tablet [Farxiga] and One tablet of placebo of dapagliflozin 10 mg in Heart Failure and Chronic Kidney Disease Post-ICU, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Planned enrollment
10th of 59
600 · median 100
Started
2025
with 4 others
Phase 3
16 of 59
5 open now
Primary completion
2029-01
later than 17 of 18 live
Registered
54th of 59
by date
Lead sponsor
2 of 59
Assistance Publique - Hôpitaux de Paris

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 10th largest by planned enrollment, is one of 5 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 17 of the 18 other live ones, and was the 54th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

Several millions of patients are admitted to ICUs in Europe or USA each year. We and others, have shown that patients discharged from intensive care units (ICU) have a high incidence of cardiovascular and/or renal events and high mortality rate (22%) during the year following ICU discharge. Furthermore, a very recent meta-analysis found an excess hazard of late cardiovascular events which persists for at least 5 years following hospital discharge in sepsis survivors. Hence, many international ICU societies recommended investigating and improving post-ICU outcome with scarce guidance. We demonstrated that the proportion of ICU patients dying or presenting cardiovascular events within the year following ICU discharge is reported \~25% [2], reaching \~40% in some studies when considering patients with acute kidney injury (AKI). Plasma biomarkers at ICU discharge have good predictive value and patients with increased kidney or cardiovascular biomarkers display high risk of such events. In addition, we and others demonstrated that AKI or sub-AKI (patient not meeting the AKI definition but with an increased kidney related biomarker) could induce remote cardio-vascular injury and fibrosis, which may be involved in the poor long-term prognosis of ICU-acquired AKI. We hypothesize that strategy that prevent worsening in cardiovascular and/or renal injuries and/or in cardiovascular consequences of sub-AKI and AKI after ICU discharge improve long-term outcomes in ICU survivors. SGLT2 inhibitors are widely recognized as key drugs to protect the kidney and/or the myocardium in chronic diseases such as diabetes or heart failure. Cardio protective effect of SGLT2 inhibitors is optimal in patients with higher cardiac biomarker.

Read the detailed description

Phase III study Prospective, multicenter, superiority, double-blind, randomized controlled study with two arms (1:1).

Every patient will be screened in the 48h before ICU discharge for trial inclusion and non-inclusion criteria until 72h hours after ICU discharge. After providing written informed consent, patients will be randomly assigned to receive either dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in accordance with the sequestered, fixed-randomization schedule, with the use of balanced blocks to ensure an approximate 1:1 ratio of the two regimens for one year.

Four visits are planned, one at inclusion (V0), one at 6 months (V1), one at the end of the treatment (V2 at one year), one 6 weeks after the end of the treatment (V3, end of the study) and two phone calls at 3 (Phone call 1) and 9 months (phone call 2).

At 6 months (V1) and at 12 months (V2) visits, a clinical exam and biological analysis will be performed at hospital (i.e., HbA1c, glucose level, ionogram, NT-proBNP or BNP, serum creatinine, hematocrit and pregnancy urinary test) by anesthesiologists, cardiologists or nephrologists, to assess primary and secondary endpoints, including eGFR.

At 12 months + 6 weeks (V3) visit, a clinical exam and biological analysis will be performed at hospital (i.e., glucose level, NT-proBNP or BNP, serum creatinine) by anesthesiologists, cardiologists or nephrologists, to assess primary and secondary endpoints, including eGFR.

The phone calls, at 3 and 9 months, will be made by the designated persons and respecting the confidentiality and security of the data collected.

At inclusion (V0) and at 6 months (V1) the treatment will be deliver for the next 6 months. At 6 months (V1), the patient will pick up his treatment at the hospital.

Primary endpoints will be assessed at 6 and 12 months visit and phone calls (3 and 9 months).

Secondary endpoints will be assessed at each visit and phone calls (3, 6, 9, 12 and 12 + 6 weeks).

eGFR (glomerular filtration rate) will be assessed only at 6, 12 months and 12 + 6 weeks. The eGFR (glomerular filtration rate) will not be assessed at phone calls.

At each visit and phone calls, adverse events and severe adverse events will also be assessed.

03

Conditions studied

  • Heart Failure and Chronic Kidney Disease Post-ICU

Keywords

  • Cardiovascular outcomes
  • Renal outcomes
  • SGLT2 inhibitors
  • Cardiorenal syndrome
  • Critical illness recovery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >or= 18 years
  • Mechanical ventilation and/or vasopressors/inotropes for more than 24h during ICU stay
  • Patients ready to be discharged from ICU according to physician in charge
  • Inform consent form signed by the patient
  • NT-proBNP greater than 800 ng/L or BNP > 90 ng/L and/or Estimated (eGFR) between 25ml/min/1.73m² and 90ml/min/1.73m² of body-surface area (CKD-EPI formula) at inclusion.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Ability to become pregnant and refusal to use effective during all study treatment Women of (WOCBP)** must agree to use adequate contraception according to Recommendations related to contraception and pregnancy testing in clinical trials, by Clinical Trial Facilitation Group (CTFG).

The inclusion of WOCBP requires use of a highly effective contraceptive measure :

  • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation

    • oral
    • intravaginal
    • transdermal
  • progestogen-only hormonal contraception associated with inhibition of ovulation

    • oral
    • injectable
    • implantable
  • intrauterine device (IUD)
  • intrauterine hormone-releasing system ( IUS)
  • bilateral tubal occlusion
  • vasectomised partner
  • sexual abstinence

The above mentioned risk mitigation measures (contraception) should be maintained during treatment and until the end of relevant systemic exposure.

** a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

  • Breast feeding
  • Known to dapagliflozin or any of the
  • Patients treated with dapagliflozin before ICU admission
  • Patients with severe cirrhosis ( C)
  • Patients who admitted or who developed during their ICU stay a urinary tract infection or a perineal infection and patients at risk of skin infection near the perineum (e.g., a sacral pressure ulcer)
  • Estimated (eGFR) below 25 ml per minute per 1.73 m2 of body-surface area (CKD -EPI formula).
  • Patient for whom treatment with Dapagliflozine is strongly recommended according to recent international guidelines:

    • patients with type 2 diabetes mellitus adults for whom the treatment is inadequately controlled as an adjunct to diet and exercise: either as monotherapy when metformin is considered inappropriate due to inadequate tolerance, or in addition to other medications for the treatment of type 2 diabetes,
    • symptomatic chronic heart failure with reduced or preserved ,
    • chronic kidney disease, in addition to standard therapy with a glomerular filtration rate (GFR) between 25 and 75 mL/min/1.73m² and a urinary albumin-to-creatinine ratio (ACR) between 200 and 5000 mg/g and treated for at least 4 weeks with an ACE inhibitor or angiotensin 2 receptor blocker (ARB II or sartan).
  • Patient without national health insurance, and patient on AME (state medical aid)
  • Persons deprived of liberty by a judicial or administrative decision
  • Participation in other interventional study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    Dapagliflozin

    One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..

    Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]

  • Placebo comparator
    Placebo of dapagliflozin

    One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.

    Drug: One tablet of placebo of dapagliflozin 10 mg

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..

  • DrugOne tablet of placebo of dapagliflozin 10 mg

    One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Time frame: Within the year after randomization

  2. Unscheduled hospital hospitalization for heart failure

    All potential hospitalizations for heart failure should be recorded in the eCRF and submitted to adjudication. The Clinical Event Adjudication (CEA) committee members will adjudicate the events as specified in the (CEA) Charter.

    Time frame: Within the year after randomization

  3. Decrease of eGFR by more than 50% from ICU discharge and/or end stage kidney disease defined as an eGFR<15ml/min/1.73m² and/or initiation of renal replacement therapy and/or kidney transplantation

    Dialysis, eGFR events (\<15 mL/min/1.73m²; ≥50% decline in eGFR) will be recorded in the eCRF and submitted for adjudication. eGFR baseline is defined as the local laboratory value at inclusion visit. The eGFR will be calculated using CKD-EPI equation without race coefficient \[87, 88\].

    Time frame: Within the year after randomization

Secondary outcomes

  1. Unscheduled hospital hospitalization for acute heart failure

    Time frame: Within the year after randomization

  2. Unscheduled hospital hospitalization for stroke

    Time frame: Within the year after randomization

  3. Unscheduled hospital hospitalization for acute coronary syndrome

    Time frame: Within the year after randomization

  4. Occurrence of severe chronic kidney disease

    Defined as eGFR \<30 ml/min/1.73m2

    Time frame: Within the year after randomization

  5. • Decrease of estimated glomerular filtration rate of more than 50% from baseline

    Time frame: Within the year after randomization

  6. New episode of acute kidney injury (according to the KDIGO criteria) requiring hospitalization

    Time frame: Within the year after randomization

  7. Occurrence of end stage kidney disease defined (eGFR<15ml/min/1.73m2) and/or initiation of renal replacement therapy and/or kidney transplantation

    Time frame: Within the year after randomization

  8. Change in NT-proBNP (pg/mL) from baseline to end of study

    Time frame: Between 12 months (end of treatment) and 12 months + 6 weeks (end of study)

  9. Occurrence of cardiovascular events

    The participants sites should record potential strokes and transit ischemic attacks (TIAs) in the eCRF and submit for adjudication. The CEA committee members will adjudicate all potential cerebrovascular events to decide if they qualify as stroke according to the criteria defined in the CEA charter

    Time frame: Within the year after randomization

  10. Occurrence of renal events

    Time frame: Within the year of treatment

  11. Urinary tract infection

    All potential events of urinary tract infection will be recorded in the eCRF and submitted to the CEA.

    Time frame: Within the year after randomization

  12. Necrotizing fasciitis

    All potential events of necrotizing fasciitis will be recorded in the eCRF and submitted to the CEA.

    Time frame: Within the year after randomization

  13. Symptomatic ketoacidosis

    This outcome is defined as Arterial pH \<7.3 and Ketone-positive urine and Anion gap \>10 mEq/L and Drowsy, stupor or coma All potential events of ketoacidosis will be recorded in the eCRF and submitted to the CEA.

    Time frame: Within the year after randomization

  14. Major hypoglycaemia

    This outcome is defined as gycemia\<3 mmol/l) and any episode of hypoglycemia for which assistance was needed, all potential major hypoglycaemia will be recorded in the eCRF and submitted to the CEA.

    Time frame: Within the year after randomization

  15. Death of any cause

    Time frame: Within the year after randomization

  16. Occurrence of global outcome events

    Events will be recorded in the eCRF and submitted to adjudication by the CEA committee for each event type. The adjudication process will ensure the thorough evaluation and classification of events based on the clinical and laboratory criteria specified in the study protocol.

    Time frame: Within the year of treatment

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Sano M, Goto S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation. 2019 Apr 23;139(17):1985-1987. doi: 10.1161/CIRCULATIONAHA.118.038881. No abstract available. PubMed 31009585 ↗
  • Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ, Choi DE. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016 Jul 8;11(7):e0158810. doi: 10.1371/journal.pone.0158810. eCollection 2016. PubMed 27391020 ↗
  • Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. PubMed 30424892 ↗
  • Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30. PubMed 32877652 ↗
  • Depret F, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Fournier MC, Jaber S, Damoisel C, Lu Q, Monnet X, Rennuit I, Darmon M, Leone M, Guidet B, Sonneville R, Montravers P, Pili-Floury S, Lefrant JY, Duranteau J, Laterre PF, Brechot N, Oueslati H, Cholley B, Struck J, Hartmann O, Mebazaa A, Gayat E, Legrand M. Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients. Am J Respir Crit Care Med. 2020 Sep 15;202(6):822-829. doi: 10.1164/rccm.201910-1950OC. PubMed 32516543 ↗
  • Legrand M, Rossignol P. Cardiovascular Consequences of Acute Kidney Injury. N Engl J Med. 2020 Jun 4;382(23):2238-2247. doi: 10.1056/NEJMra1916393. No abstract available. PubMed 32492305 ↗
  • Gayat E, Cariou A, Deye N, Vieillard-Baron A, Jaber S, Damoisel C, Lu Q, Monnet X, Rennuit I, Azoulay E, Leone M, Oueslati H, Guidet B, Friedman D, Tesniere A, Sonneville R, Montravers P, Pili-Floury S, Lefrant JY, Duranteau J, Laterre PF, Brechot N, Chevreul K, Michel M, Cholley B, Legrand M, Launay JM, Vicaut E, Singer M, Resche-Rigon M, Mebazaa A. Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Crit Care. 2018 Jan 18;22(1):8. doi: 10.1186/s13054-017-1922-8. PubMed 29347987 ↗
  • Arrigo M, Feliot E, Gayat E, Mebazaa A. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. Int J Cardiol. 2018 Nov 1;270:203. doi: 10.1016/j.ijcard.2018.07.080. Epub 2018 Jul 20. No abstract available. PubMed 30045823 ↗
  • Depret F, Chousterman B, Roger C, Garnier M, Lalande R, Kerforne T, Rouve E, Lukaszewicz AC, Ouattara A, Merdji H, Turbil E, Bouhemad B, Quenot JP, Delbove A, Levrat Q, Jully M, Legriel S, Bougouin W, Klouche K, Kimmoun A, Asfar P, Vicaut E, Mebazaa A. Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU). BMJ Open. 2026 Apr 16;16(4):e108119. doi: 10.1136/bmjopen-2025-108119. PubMed 41991273 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be shared. The data will be anonymized to protect participants' privacy. Researchers may request access to the data by contacting the Steering Committee, which will review the request within two months. The data will be available one year after publication.

Time frame: The data will be available one year after publication, for 5 years

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2029, 37 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 37 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
Jun 17, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Jan 15, 2029
CompletionEst.
Jan 15, 2029
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025629
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Dec 2, 2025
Primary completion
Jan 15, 2029 (estimated)
Completion
Jan 15, 2029 (estimated)
Last update
Feb 23, 2026

Study contacts

François DEPRET, MD-PHD
Contact
francois.depret@aphp.fr
0142499570 ext. 0033
Alexandre MEBAZAA, MD-PhD
Contact
alexandre.mebazaa@aphp.fr
01 49 95 80 85 ext. 0033
Alexandre Mebazaa, MD-PHD
principal investigator · APHP
François DEPRET, MD-PHD
study chair · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion